Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

The predictors of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and evaluate post-progression treatment and outcomes. We retrospectively enrolled 10...

Full description

Bibliographic Details
Main Authors: I-Cheng Lee, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou, Yi-Hsiang Huang
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
sorafenib
regorafenib
progression-free survival
overall survival
post-progression survival
Online Access:https://www.mdpi.com/2072-6694/14/8/2014

Similar Items

Similar Items